Evotec SE (EVO)
NASDAQ: EVO · Real-Time Price · USD
3.995
+0.015 (0.38%)
At close: Aug 1, 2025, 4:00 PM
3.980
-0.040 (-1.00%)
Pre-market: Aug 4, 2025, 4:02 AM EDT

Company Description

Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally.

It operates in two segments, Shared R&D and Just – Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic disease, and rare diseases; central nervous system (CNS) and cardiometabolic diseases; and animal and women health.

The company has collaboration agreements with Mass General Brigham and Joslin Diabetes Center focusing on cardiometabolic diseases; BMS antiviral; Novo Nordisk cell therapy; University of Oxford; German Cancer Research Center; University Hospital in Hamburg; University of Toronto, Harvard, and Yale; Johns Hopkins University; Ospedale San Raffaele (OSR); and National University of Singapore.

It has a partnership with LAB282, LAB150, beLAB2122, beLAB1407, LAB eN², Danube Labs, VC Amplitude Ventures, LaB eN2, and 65LAB.

The company serves pharma and biotechnology companies, academic institutions, patient advocacy groups, and venture capital.

The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

Evotec SE
Evotec SE logo
CountryGermany
Founded1993
IPO DateNov 4, 2021
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
Employees4,740
CEOChristian Wojczewski

Contact Details

Address:
Essener Bogen 7
Hamburg, 22419
Germany
Phone49 40 560 81 0
Websiteevotec.com

Stock Details

Ticker SymbolEVO
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyEUR
IPO Price$26.16
CIK Code0001412558
CUSIP Number30050E105
ISIN NumberUS30050E1055
SIC Code2834

Key Executives

NamePosition
Dr. Christian Wojczewski Ph.D.Chief Executive Officer and Management Board Member
Dr. Cord Dohrmann Ph.D.Chief Scientific Officer and Member of Management Board
Aurelie DalbiezChief People Officer and Member of Management Board
Paul HitchinChief Financial Officer and Member of Management Board
Volker BraunExecutive Vice President and Head of Global Investor Relations and ESG
Dr. Christian DargelExecutive Vice President Global Head of Legal and Compliance
Dr. Ian M. HunneyballSenior Vice President of Programme Management and Clinical Operations
Dr. David HalletExecutive Vice President
Uwe AndagExecutive Vice President Head of Metabolic Diseases
Christiane HonischSVice President Head of Diagnostics

Latest SEC Filings

DateTypeTitle
Jul 30, 20256-KReport of foreign issuer
Jul 21, 20256-KReport of foreign issuer
Jun 3, 20256-KReport of foreign issuer
May 6, 20256-KReport of foreign issuer
Apr 17, 202520-FAnnual and transition report of foreign private issuers
Apr 17, 20256-KReport of foreign issuer
Apr 17, 20256-KReport of foreign issuer
Nov 29, 20246-KReport of foreign issuer
Nov 22, 20246-KReport of foreign issuer
Nov 15, 20246-KReport of foreign issuer